Literature DB >> 15310681

Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II).

P W Serruys1, P A Lemos, B A van Hout.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15310681      PMCID： PMC1768447          DOI： 10.1136/hrt.2003.028811

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  8 in total

1.  A framework for cost-effectiveness analysis from clinical trial data.

Authors:  A O'Hagan; J W Stevens
Journal:  Health Econ       Date:  2001-06       Impact factor: 3.046

2.  ARTS I -- the rapamycin eluting stent; ARTS II -- the rosy prophecy.

Authors:  P W Serruys
Journal:  Eur Heart J       Date:  2002-05       Impact factor: 29.983

3.  Costs, effects and C/E-ratios alongside a clinical trial.

Authors:  B A van Hout; M J Al; G S Gordon; F F Rutten
Journal:  Health Econ       Date:  1994 Sep-Oct       Impact factor: 3.046

4.  Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.

Authors:  P W Serruys; F Unger; J E Sousa; A Jatene; H J Bonnier; J P Schönberger; N Buller; R Bonser; M J van den Brand; L A van Herwerden; M A Morel; B A van Hout
Journal:  N Engl J Med       Date:  2001-04-12       Impact factor: 91.245

5.  Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery.

Authors:  S J Pocock; R A Henderson; A F Rickards; J R Hampton; S B King; C W Hamm; J Puel; W Hueb; J J Goy; A Rodriguez
Journal:  Lancet       Date:  1995-11-04       Impact factor: 79.321

6.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

7.  Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up.

Authors:  Muzaffer Degertekin; Patrick W Serruys; David P Foley; Kengo Tanabe; Evelyn Regar; Jeroen Vos; Peter C Smits; Wim J van der Giessen; Marcel van den Brand; Pim de Feyter; Jeffrey J Popma
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

Review 8.  Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.

Authors:  Pedro A Lemos; Chi-hang Lee; Muzaffer Degertekin; Francesco Saia; Kengo Tanabe; Chourmouzios A Arampatzis; Angela Hoye; Marco van Duuren; Giorgios Sianos; Pieter C Smits; Pim de Feyter; Willem J van der Giessen; Ron T van Domburg; Patrick W Serruys
Journal:  J Am Coll Cardiol       Date:  2003-06-04       Impact factor: 24.094
  8 in total
  2 in total

1.  Utility of drug-eluting stents in complex lesions and high-risk patients.

Authors:  Eugenia Nikolsky; Gregg W Stone
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-02

2.  The SYNTAX Score Can Predict Major Adverse Cardiac Events Following Percutaneous Coronary Intervention.

Authors:  Hadi Safarian; Mohammad Alidoosti; Akbar Shafiee; Mojtaba Salarifar; Hamidreza Poorhosseini; Ebrahim Nematipour
Journal:  Heart Views       Date:  2014 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.